PresentationGood morning, everyone, and welcome to the last day of the 2026 J.P. Morgan Healthcare Conference. My name is Ben Davis. I'm an associate with the Healthcare Investment Banking team at JPMorgan. And I'm pleased to introduce Richard Adcock, CEO; and David Sachs, CFO of ImmunityBio. Richard will be running through his presentation, after which we'll have some time for questions and answers.Richard AdcockPresident, CEO & Director Thank you. Thanks for everybody being here, and thanks, [ Benjamin ] ...

Core Insights - The FDA granted accelerated approval to Bayer AG's Hyrnuo (sevabertinib) for adults with advanced lung cancer characterized by HER2 tyrosine kinase domain activating mutations [1][3] - The Oncomine Dx Target Test was approved as a companion diagnostic to identify eligible patients for sevabertinib treatment [2] - Amgen Inc.'s Imdelltra received full approval for extensive stage small cell lung cancer, showing a 40% reduction in death risk and extending median overall survival by over five months compared to standard chemotherapy [5] Bayer AG and Hyrnuo - Hyrnuo's monthly list price is set at $24,000 [3] - In a study involving 70 patients, the confirmed objective response rate (ORR) was 71%, with a median duration of response (DOR) of 9.2 months; 54% of responding patients had a DOR of six months or more [3] - Among 52 patients, the ORR was 38%, with a median DOR of 7.0 months; 60% of responding patients had a DOR of six months or more [4] - The recommended dosage for sevabertinib is 20 mg orally twice daily with food until disease progression or unacceptable toxicity [4] Amgen Inc. and Imdelltra - Imdelltra received full FDA approval for patients with extensive stage small cell lung cancer who experienced disease progression after platinum-based chemotherapy [5] - The global Phase 3 DeLLphi-304 study demonstrated a 40% reduction in the risk of death and significantly extended median overall survival by more than five months compared to standard of care chemotherapy [5]

Core Insights - CEO.CA is a leading investor social network focused on junior resource and venture stocks, providing exclusive updates to CEOs of junior mining explorers [1][6] - The platform has gained popularity since its founding in 2012, attracting millions of global investors to discuss stocks, commodities, and emerging companies [2][6] - The "Inside the Boardroom" series offers insights from industry leaders, enhancing understanding of their vision and strategies [3][4] Company Highlights - Dr. John Yu, CEO of Kairos Pharma, discussed the company's prostate cancer trial, which reported zero grade 3 or 4 toxicities, a significant improvement compared to over 50% with standard treatments [4] - The upcoming efficacy data in September and plans for expansion into lung cancer and other tumor types were also highlighted [4][8] - CEO.CA serves as a platform for showcasing companies and connecting with investors, emphasizing its role in the investment community [5][6]

Core Insights - The combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib) has been approved by the China National Medical Products Administration (NMPA) for treating patients with locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer (NSCLC) with MET amplification after progression on EGFR TKI therapy [1][2][3] - This combination treatment is the only all-oral option available for these patients, providing a chemotherapy-free approach [1][3] - The SACHI Phase III trial demonstrated a 66% reduction in the risk of disease progression or death compared to platinum-based chemotherapy, with a median progression-free survival (PFS) of 8.2 months for the combination versus 4.5 months for chemotherapy [1][3][12] Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery and commercialization of targeted therapies for cancer and immunological diseases [15] - The approval of the ORPATHYS and TAGRISSO combination marks a significant milestone in HUTCHMED's mission to address MET-driven progression in NSCLC patients [3][15] - AstraZeneca collaborates with HUTCHMED to market both ORPATHYS and TAGRISSO in China, enhancing the reach of this new treatment option [3][15] Industry Context - Lung cancer is the leading cause of cancer death, with NSCLC accounting for 80-85% of cases [5] - Approximately 30-40% of NSCLC patients in Asia have EGFR mutations, highlighting the need for effective treatment options [5][6] - MET amplification is a common mechanism of acquired resistance to EGFR TKI therapy, affecting 15-50% of patients who experience disease progression [11][12]